Trial Profile
A clinical study of Apatinib combined TACE in treating intermediate and advanced hepatocellular carcinoma
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 03 Jul 2017 New trial record